echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Front Oncol: The prognostic role of the number of resected lymph nodes in stage II small bowel adenocarcinoma (SBA) based on the SEER database

    Front Oncol: The prognostic role of the number of resected lymph nodes in stage II small bowel adenocarcinoma (SBA) based on the SEER database

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Treatment strategies for small bowel adenocarcinoma (SBA) are controversial due to the lack of large-scale clinical trials, especially in stage II patients
    .


    According to the National Comprehensive Cancer Network (NCCN) guidelines, insufficient examination of lymph nodes (LNs) (<5 duodenum and <8 primary sites of jejunum/ileum) is one of the high-risk factors for stage II patients, and adjuvant chemotherapy is recommended


    Treatment strategies for small bowel adenocarcinoma (SBA) are controversial due to the lack of large-scale clinical trials, especially in stage II patients


    However, since 2004, surgical approaches and chemotherapy strategies for SBA patients have changed considerably


    A total of 935 patients with stage II SBA met the inclusion criteria, including 413 (44.
    2%) in duodenum and 522 (55.
    8%) in jejunum and ileum
    .


    The two groups of patients were similar in gender, age, grade, ethnicity and region


    A total of 935 patients with stage II SBA met the inclusion criteria, including 413 (44.


    The Optimal Number of Lymph Nodes Resection Study found that in patients with duodenal cancer who had at least 5 LNs removed (HR: 0.
    39, 95% CI, 0.
    26 to 0.
    58, Pearson's chi-square: 20.
    69, p < 0.
    0001) and jejunum/ileum The difference in survival was greatest among cancer patients who had at least 12 LNs removed (HR: 0.
    71, 95% CI, 0.
    52 to 0.
    98, Pearson's chi-square: 4.
    253, p = 0.
    0392)
    .

    The Optimal Number of Lymph Nodes Resection Study found that in patients with duodenal cancer who had at least 5 LNs removed (HR: 0.
    39, 95% CI, 0.
    26 to 0.
    58, Pearson's chi-square: 20.
    69, p < 0.
    0001) and jejunum/ileum The difference in survival was greatest among cancer patients who had at least 12 LNs removed (HR: 0.
    71, 95% CI, 0.
    52 to 0.
    98, Pearson's chi-square: 4.
    253, p = 0.
    0392)
    .


    The Optimal Number of Lymph Nodes Resection Study found that in patients with duodenal cancer who had at least 5 LNs removed (HR: 0.


    Multivariate Cox analysis showed that we could see that older age (≧45 years), T4 and higher histological grade were negative prognostic factors
    .


    Patients with jejunal/ileal tumors had better CSS than duodenal tumors (HR: 0.


    Multivariate Cox analysis showed that we could see that older age (≧45 years), T4 and higher histological grade were negative prognostic factors


    Taken together, the study demonstrated that the number of resected LNs was an important prognostic factor for survival in patients with stage II SBA
    .


    The number of LNs examined <5 remains a high risk factor for duodenal tumors, but the breakdown point for jejunal/ileal tumors should rise from 8 to 12


    Taken together, the study demonstrated that the number of resected LNs was an important prognostic factor for survival in patients with stage II SBA


    Original source:

    Original source:

    Liu Z, Liu K, Gao J, Jing C, Ma Y, Zheng S and Shan J (2022) Prognostic Value of Lymph Node Evaluation in Stage II Small Bowel Adenocarcinoma: An Updated Analysis of Surveillance, Epidemiology, and End Results Database.


    Liu Z, Liu K, Gao J, Jing C, Ma Y, Zheng S and Shan J (2022) Prognostic Value of Lymph Node Evaluation in Stage II Small Bowel Adenocarcinoma: An Updated Analysis of Surveillance, Epidemiology, and End Results Database.
    Front .
    Oncol.
    12:865745.
    doi: 10.
    3389/fonc.
    2022.
    865745Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.